索拉非尼与舒尼替尼单药治疗晚期肝细胞癌的效果分析

Effects of Sorafenib or Sunitinib on the Treatment of the Advanced Hepatocellular Carcinoma

目的:对比索拉非尼(Sorafenib)和舒尼替尼(Sunitinib)单药治疗晚期肝细胞癌的疗效及安全性。方法:对我院2004年1月-2010年10月收治的44例晚期肝细胞肝癌患者的临床资料进行回顾分析。根据不同给药方式,将患者分为两组。其中,索拉非尼组32例患者采取口服索拉非尼进行治疗,而舒尼替尼组12例患者给予口服舒尼替尼治疗。观察并比较两组患者的治疗效果及药物不良反应情况。结果:索拉非尼组总生存时间为6.3月,1年生存率为16%,肿瘤进展时间为3个月,疾病控制率为71%;舒尼替尼组总生存时间为4.7月,1年生存率为8%,肿瘤进展时间为3个月,疾病控制率为64%。两组临床效果差异无统计学意义(P=0.2415,0.5706,0.7132)。索拉非尼组患者手足皮肤反应、中性粒细胞减少及肝损伤等主要毒副反应的发生率均低于舒尼替尼组,差异具有统计学意义(P>0.05)。结论:索拉非尼治疗晚期肝细胞肝癌的临床效果与舒尼替尼具有很好的一致性,药物不良反应相对较轻,患者依从性较好,值得临床推广应用。

Objective： To observe the clinical efficacy of sorafenib and sunitinib on the treatment of the advanced hepatocellular carcinoma, and to discuss the adverse reactions to patients. Methods： A retrospective analysis was performed on the clinical data of 44 patients with hepatocellular carcinoma who were treated in our hospital from January 2004 to October 2010. According to the different medication modes, the patients were divided into two groups. Then the clinical effects and adverse reactions were observed and compared between the two groups. Results： In the sorafenib group, the MOS was 6.3 months, the rate of one-year＇s survival was 16%, the MTTP was 3 months and the rate of disease control was 71%; In the sunitinib group, the MOS was 4.7 months, the rate of one-year＇s survival was 8%, the MTTP was 3 months and the rate of disease control was 64%. There was no statistically significant differences about the clinical efficacy between the two groups （P=0.2415, 0.5706, 0.7132）. The incidence of adverse reactions in the sorafenib group was lower that that of the sunitinib group with statistically significant difference （P〈0.05）. Conclusions： It is indicated that the sorafenib should be well promoted and make contribution to the treatment of the advanced hepatocellular carcinoma with the advantage of high consistency in accuracy and safety.